1. A method for predicting multiple sclerosis (MS) disease relapse, guiding MS
disease therapy, and/ or predicting MS disease outcome in a clinically definite
multiple sclerosis (CDMS) subject, the method comprising the steps of:
obtaining a blood sample from the subject;
assaying the blood sample to detect expression levels of one or more biomarkers, wherein the one or more biomarkers comprise prohibitin-1; and comparing the biomarker expression levels to a control sample or to a sample taken from the same patient before or during treatment or during remission, wherein relative increase in expression level of prohibitin-1 in lymphocytes of the sample compared to the lymphocytes in the control sample or to a sample taken from the same patient before or during treatment or during remission is indicative of subclinical MS disease activity in the subject.
2. The method of claim 1, wherein the one or more biomarkers are assayed using
one or more techniques selected from fluorescence assisted cell sorting (FACS),
western blotting, immunoassays, immunoprecipitation, gene chip expression
analysis, two-dimensional gel electrophoresis, mass spectroscopy or laser
densitometry.
3. The method of claim 1, wherein said assaying comprises:
pretreating the sample with a lyse solution to lyse erythrocytes;
incubating the sample with one or more antibodies; and
assaying the sample in a flow cytometer to identify prohibitin-1 staining in lymphocytes

4. The method of claim 3, wherein the one or more antibodies comprise a detection
marker-conjugated antibody.
5. The method of claim 3, wherein the one or more antibodies comprise a
monoclonal antibody.
6. The method of claim 1, wherein the control sample is selected from a healthy
subject, a subject with remission MS, a subject with optic neuritis, and a subject
with other neurological disorder.
7. The method of claim 1, wherein the relative increase in prohibitin-1 expression is at least 1.5 fold over the control sample.
8. The method of claim 1, wherein the subject was treated with one or more drugs prior to obtaining the sample.
9. The method of claim 8, wherein the subclinical disease activity is indicative of effectiveness of the one or more drugs in the subject.
10. The method of claim 1, wherein the subclinical MS disease activity is indicative
of imminent relapse in the subject.